BioMarin (BMRN) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
2.9B
Gross Profit
2.3B
79.67%
Operating Income
474.2M
16.62%
Net Income
426.9M
14.96%
Balance Sheet Metrics
Total Assets
7.0B
Total Liabilities
1.3B
Shareholders Equity
5.7B
Debt to Equity
0.24
Cash Flow Metrics
Operating Cash Flow
588.0M
Free Cash Flow
475.4M
Revenue & Profitability Trend
BioMarin Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.9B | 2.4B | 2.1B | 1.8B | 1.9B |
| Cost of Goods Sold | 580.2M | 514.9M | 483.7M | 470.5M | 524.3M |
| Gross Profit | 2.3B | 1.9B | 1.6B | 1.4B | 1.3B |
| Operating Expenses | 1.8B | 1.7B | 1.5B | 1.4B | 1.4B |
| Operating Income | 474.2M | 158.1M | 46.0M | -74.3M | -91.8M |
| Pre-tax Income | 541.8M | 188.6M | 149.6M | -75.4M | -49.0M |
| Income Tax | 114.9M | 20.9M | 8.0M | -11.3M | -903.0M |
| Net Income | 426.9M | 167.6M | 141.6M | -64.1M | 854.0M |
| EPS (Diluted) | - | $0.87 | $0.75 | -$0.35 | $4.53 |
Income Statement Trend
BioMarin Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 3.2B | 3.0B | 2.8B | 2.3B | 2.3B |
| Non-Current Assets | 3.8B | 3.9B | 3.6B | 3.7B | 3.5B |
| Total Assets | 7.0B | 6.8B | 6.4B | 6.0B | 5.8B |
| Liabilities | |||||
| Current Liabilities | 607.0M | 1.2B | 588.9M | 546.5M | 492.5M |
| Non-Current Liabilities | 724.0M | 713.0M | 1.2B | 1.2B | 1.2B |
| Total Liabilities | 1.3B | 1.9B | 1.8B | 1.7B | 1.7B |
| Equity | |||||
| Total Shareholders Equity | 5.7B | 5.0B | 4.6B | 4.3B | 4.1B |
Balance Sheet Composition
BioMarin Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 426.9M | 167.6M | 141.6M | -64.1M | 854.0M |
| Operating Cash Flow | 588.0M | 101.4M | 295.1M | 301.2M | 18.5M |
| Investing Activities | |||||
| Capital Expenditures | -85.4M | -96.7M | -121.0M | -95.6M | -114.3M |
| Investing Cash Flow | 148.5M | -100.3M | -9.4M | -342.7M | -30.4M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -575.7M | -88.1M | -88.0M | -49.2M | 109.2M |
| Free Cash Flow | 475.4M | 51.6M | 44.4M | 185.3M | -52.2M |
Cash Flow Trend
BioMarin Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
20.03
Forward P/E
18.09
Price to Book
1.79
Price to Sales
3.52
PEG Ratio
18.09
Profitability Ratios
Profit Margin
17.76%
Operating Margin
30.05%
Return on Equity
9.64%
Return on Assets
6.38%
Financial Health
Current Ratio
5.52
Debt to Equity
10.39
Beta
0.18
Per Share Data
EPS (TTM)
$2.70
Book Value per Share
$30.21
Revenue per Share
$15.48
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| bmrn | 10.4B | 20.03 | 1.79 | 9.64% | 17.76% | 10.39 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Alnylam | 40.8B | - | 353.42 | -414.62% | -11.49% | 2,358.26 |
| Royalty Pharma plc | 20.3B | 14.75 | 2.30 | 18.00% | 48.26% | 77.82 |
| Insmed | 20.0B | - | 193.43 | -320.20% | -265.93% | 1,316.96 |
Financial data is updated regularly. All figures are in the company's reporting currency.